Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07D AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/076611NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER
WO 14.04.2022
Int.Class A61K 31/4166
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4166having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
Appl.No PCT/US2021/053846 Applicant THE PENN STATE RESEARCH FOUNDATION Inventor MISRA, Sougat
Disclosed herein are compositions and methods for increasing the expression of human SLC7A11. The compositions include a combination of compounds that exhibit anti-proliferative activity against cancer cells. The compositions and methods can be used to treat a subject with cancer. Disclosed are also compositions and methods of treating a coronavirus infection, Zika virus, influenza virus infection, human immunodeficiency virus (HIV), or Rhinovirus.
2.WO/2024/092209VITAMIN-BASED LIPIDS AND LIPID NANOPARTICLES COMPRISING THE SAME
WO 02.05.2024
Int.Class C07D 311/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
311Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
02ortho- or peri-condensed with carbocyclic rings or ring systems
04Benzo pyrans, not hydrogenated in the carbocyclic ring
Appl.No PCT/US2023/078044 Applicant ADVANCED RNA VACCINE (ARV) TECHNOLOGIES, INC. Inventor XU, Jiangsheng
Described are compounds, compositions, and methods for delivery of therapeutic, diagnostic, or prophylactic agents (for example, a nucleic acid).
3.WO/2023/014758INHIBITORS FOR CORONAVIRUSES
WO 09.02.2023
Int.Class C07D 207/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
18having one double bond between ring members or between a ring member and a non-ring member
22with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
24Oxygen or sulfur atoms
262-Pyrrolidones
Appl.No PCT/US2022/039233 Applicant COCRYSTAL PHARMA, INC. Inventor JACOBSON, Irina, C.
Provided are compounds of Formula (I), Formula (la), Formula (lb), and their use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, of reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and of treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound of Formula (I), Formula (la), Formula (lb), or a pharmaceutically acceptable salt thereof.
4.WO/2023/059792CORONAVIRUS NON-STRUCTURAL PROTEIN 3 DEGRADING COMPOUNDS
WO 13.04.2023
Int.Class C07D 235/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
235Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
02condensed with carbocyclic rings or ring systems
04Benzimidazoles; Hydrogenated benzimidazoles
24with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
26Oxygen atoms
Appl.No PCT/US2022/045889 Applicant C4 THRAPEUTICS, INC. Inventor DUPLESSIS, Martin
This invention provides advantageous compounds for the treatment of hosts, including humans, infected with a coronavirus, including but not limited to SARS-CoV-2.
5.20230131564INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION
US 27.04.2023
Int.Class C07D 207/267
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
18having one double bond between ring members or between a ring member and a non-ring member
22with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
24Oxygen or sulfur atoms
262-Pyrrolidones
263with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
267with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
Appl.No 17917959 Applicant COCRYSTAL PHAEMA, INC. Inventor Irina C. Jacobson

Methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, of reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and of treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound of Table A, or a pharmaceutically acceptable salt thereof.

6.WO/2022/047128METHOD FOR TREATING COMPLEMENT MEDIATED DISORDERS CAUSED BY BETACORONAVIRUSES
WO 03.03.2022
Int.Class A61K 31/416
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
416condensed with carbocyclic ring systems, e.g. indazole
Appl.No PCT/US2021/047901 Applicant ALEXION PHARMACEUTICALS, INC. Inventor VARDI, Moshe
The present disclosure provides methods and compositions useful for diagnosing and treating activated alternative pathway of complement in a human subject with a SARS-CoV-2 infection. Also provided are methods of treating an infection by a betacoronavirus, e.g., SARS-CoV, MERS-CoV, or SARS-CoV-2, in a human subject. The methods of treatment include administering to the human subject a therapeutically effective amount of at least one complement factor D inhibitor. Also provided herein are compounds for treating an infection by a betacoronavirus and their use in the manufacture in a medicament for treating an infection by a betacoronavirus.
7.WO/2021/188620PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION
WO 23.09.2021
Int.Class C07D 263/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
263Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
02not condensed with other rings
08having one double bond between ring members or between a ring member and a non-ring member
10with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Appl.No PCT/US2021/022680 Applicant COCRYSTAL PHARMA INC. Inventor JACOBSON, Irina C.
Peptidomimetic N5-methyl-N2-(nonanoyl-L-leucyl)-L-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds for use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, for use in reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and for use in treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound represented by formulae I or II, or a pharmaceutically acceptable salt thereof. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. page 99 to page 271; examples 1 to 3; compounds A1 to A104 and Bl to B66; tables A to E).
8.WO/2021/206876INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION
WO 14.10.2021
Int.Class C07K 5/062
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04containing only normal peptide links
06Dipeptides
062the side chain of the first amino acid being acyclic, e.g. Gly, Ala
Appl.No PCT/US2021/022656 Applicant COCRYSTAL PHARMA, INC. Inventor JACOBSON, Irina, C.
Compounds of Formula (I) and methods of inhibiting the replication of viruses in a biological sample or patient, of reducing the amount of viruses in a biological sample or patient, and of treating a virus infection in a patient, comprising administering to said biological sample or patient an effective amount of a compound represented by Formula (I), a compound of Table A or B or a pharmaceutically acceptable salt thereof.
9.WO/2022/120195METHOD OF TREATING AND PREVENTING VIRAL INFECTION
WO 09.06.2022
Int.Class A61K 31/41
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
Appl.No PCT/US2021/061847 Applicant THE GENERAL HOSPITAL CORPORATION Inventor MOOTHA, Vamsi
A method of treating and preventing viral infection in a subject comprising administering an effective amount of one or more inhibitors of folate or one-carbon metabolism pathways to the subject.
10.WO/2021/152131CO-CRYSTALS AND SALTS OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE
WO 05.08.2021
Int.Class C07D 215/38
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
215Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
02having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
16with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
38Nitrogen atoms
Appl.No PCT/EP2021/052165 Applicant ABIVAX Inventor MENEGOTTO, Jérôme
The present invention relates to co-crystals and pharmaceutically acceptable salts of 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine, pharmaceutical compositions comprising them as well as their use as medicines and more particularly for use in the prevention and/or treatment of inflammatory diseases, diseases caused by viruses and/or cancer or dysplasia. The present invention also concerns methods for the preparation of said co-crystals and said pharmaceutically acceptable salts.